R-MVST Cells Show Promise for Treating Refractory Viral Infections
A clinical trial is assessing the safety and feasibility of R-MVST cells for patients with refractory viral infections caused by EBV, CMV, ADV, or BK virus.
Therapeutic Area
Therapeutic area intelligence for Cell Therapy with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.